5. Conclusions
Our study demonstrates the first proteomics characteristic of SMPP and GMPP and provides FCGBP as new serum biomarker indicating the progress of SMPP. In addition, sirolimus, a MTOR inhibitor, is a promising drug target for the treatment of SMPP.
Acknowledgments. We would like to thank all patients who donate their serum sample selflessly.
Disclaimer. The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Funding. This study was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) (Grant No. 2019-I2M-1-003), Natural Science Foundation of China (81741060) and Beijing Municipal Natural Science Foundation (7182051).
Conflict of interest statement. All authors declare that there is no conflict of interest.